Gene mutations were found in acute myeloid leukemia (AML) and their importance has been noted. To clarify the importance and stability of mutations, we examined gene mutations in paired samples at diagnosis and relapse of 34 adult AML patients. Five acquired gene mutations were detected at relapse. Of the 45 gene mutations at diagnosis, 11 of them were lost at relapse. The acquired mutations at relapse were all class I mutations as Fms-like tyrosine kinase 3 (FLT3) and rat sarcoma viral oncogene homolog (RAS) mutations. The disappeared mutations at relapse were 3 of 11 internal tandem duplications of FLT3 (FLT3-ITD) (27.3%), 3 of 3 FLT3 tyrosine kinase domain (FLT3-TKD) (100%), 3 of 13 Nucleophosmin 1 (23.1%) and 2 of 5 CCAAT/enhancer-binding protein-a (40%) mutations. However, epigenetics-modifying gene (DNMT3a, TET2 and IDH1/2) mutations had no change between diagnosis and relapse samples, and may become minimal residual disease marker. The frequency of FLT3-ITD at relapse in patients with DNMT3a mutation at diagnosis is significantly higher than those in patients without them (P ¼ 0.001). Moreover, the high frequency of FLT3-ITD at relapse is also seen in AML cases that initially present with any epigenetics-modifying gene mutations (Po0.001). Our results indicate that epigenetics-modifying gene mutations may cause genetic instability and induce FLT3-ITD, leading to resistance to therapy and relapse.
INTRODUCTION
Although acute myeloid leukemia (AML) has been considered a fatal disease, developments in anticancer drugs and supportive therapies, as well as hematopoietic stem cell transplantation, have rendered it potentially curable. Despite carrying out these therapies, however, many AML cases relapse. Such cases become refractory even to agents that were initially effective, leading to a poor prognosis. For instance, the rate of remission greatly decreases in re-induction therapy following relapse compared with induction therapy for de novo AML. 1, 2 Although many groups have investigated the resistance to therapy following relapse, the mechanisms underlying this phenomenon remain unclear.
Cytogenetic abnormalities are clearly involved in AML pathogenesis. Clinical studies have demonstrated that 'recurrent chromosomal abnormalities' are related to the onset and type of AML, as well as the responsiveness to treatment. [3] [4] [5] Indeed, complex chromosomal abnormalities and additional chromosomal abnormalities render patients highly resistant to therapy. 6, 7 With advances in mutational analysis, it is now clear that mutations in Fms-like tyrosine kinase 3 (FLT3), Nucleophosmin 1 (NPM1), and CCAAT/enhancer-binding protein alpha (C/EBPa) have an important role in AML prognosis. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Studies to date have demonstrated that many of these mutations, when they exist alone, are insufficient to cause leukemia. [18] [19] [20] This is likely because two different types of mutations, that is, class I mutations that promote cell proliferation (for example, FLT3 and c-kit mutations), and class II mutations that inhibit cell differentiation (for example, C/EBPa and NPM1 mutations) need to occur simultaneously for the onset of AML. 21, 22 It was also reported that mutations in DNA-methyltransferase 3 alpha (DNMT3a), isocitrate dehydrogenase (IDH1/2) and tet methylcytosine dioxygenase 2 (TET2) are detected with high frequency in AML. [23] [24] [25] [26] [27] [28] [29] As these are DNA methylation-regulating 'epigenetics-modifying genes,' they can be considered a third type of genetic abnormality that contributes to genetic instability. Indeed, these mutations are found at high frequency in conjunction with other mutations, 22, 23, 30 supporting the hypothesis that genetically unstable preleukemic cells acquire numerous mutations and chromosomal abnormalities, resulting in a stepwise progression to the onset of leukemia.
Mutations may be involved in resistance to AML therapy. Supporting this, subclones harboring several different types of mutations are observed in leukemia at diagnosis. [31] [32] [33] The few subclones that existed at diagnosis reportedly become dominating clones at relapse. We previously reported that in some cases, a minor population of leukemia cells that harbored c-kit mutations at diagnosis of t(8;21)AML had become dominant at relapse. 34 On the basis of such observations, leukemic clones that were not dominating at diagnosis are thought to confer resistance to therapy, given the mutations they harbor, and acquire new genetic abnormalities, thereby leading to relapse.
Examining the evolution of founding and relapse clones, and analyzing the mutations in relapsed AML that existed at diagnosis are important to address this hypothesis. Yet, only few such studies have been performed. Moreover, given that a number of mutations are related to the onset of AML, there are efforts to use these mutations as minimal residual disease (MRD) markers, 35 as well as developing molecular target drugs that target these mutations. 36, 37 Notwithstanding, only a few studies have been carried out that address the possibility that these mutations are lost at relapse or, conversely, the possibility that new mutations are acquired at relapse.
In this study, we analyzed paired initial and relapsed AML samples to determine how AML mutations, which are being clinically applied for prognosis, are involved in relapse.
MATERIALS AND METHODS

Patients and samples
Excluding treated AML cases with t(15;17)(q22;q21), t(8;21)(q22;q22), inv(16)(p13q22) and t(16;16)(p13;q22), we retrospectively analyzed pair samples at diagnosis and relapse of relapsed de novo AML cases at Nippon Medical School Hospital, or its associated facilities, between January 2001 and December 2011. Samples were bone marrow or peripheral blood specimens that comprised 420% blasts. This study was approved by the institutional review board of our hospital. Genetic analysis was performed after obtaining informed consent from patients.
Genomic DNA extraction
Mononuclear cells from bone marrow or peripheral blood were isolated by density-gradient centrifugation using lymphocyte separation medium (Organon, Durham, NC, USA). Genomic DNA of mononuclear cells was extracted with the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). PCR amplification of DNA samples was carried out essentially as described previously. 38, 39 Mutational analysis PCR-based mutational analysis of FLT3-ITD and partial tandem duplication of myeloid/lymphoid or mixed-lineage leukemia (MLL-PTD). For the analysis of internal tandem duplications of FLT3 (FLT3-ITD) mutations, the following primer set was used to PCR amplify the region containing full length JM and TK domains: forward primer: 5 0 -CAATTTAGGTATGAAAGCC-3 0 , reverse primer:
Many of the mutations in MLL-PTD involve the fusion of exons 2-6 or 2-8 to a region of intron 1 near exon 2 of the MLL gene. 40, 41 A forward primer (5 0 -GTCCAGAGCAGAGCAAACAG-3 0 ) directed to exon 7 and reverse primer (5 0 -GATGAAGAAGTCAGAGTGCG-3 0 ) directed to exon 2 was used to determine the size of the MLL-PTD insertion region. Moreover, a reverse primer directed to intron 8 was used as an internal control.
PCR-restriction fragment length polymorphism analysis for the FLT3-TKD D835Y mutation. The point mutation in FLT3 tyrosine kinase domain (FLT3-TKD D835Y) was confirmed using the following primers: 5 0 -CCA GGAACGTGCTTGTCA-3 0 and 5 0 -TCAAAAATGCACCACAGTGAG-3 0 . We confirmed the presence or absence of mutations by EcoRV restriction enzyme digestion following PCR amplification.
Mutational analyses of NPM1, C/EBPa, N-RAS, K-RAS, DNMT3a, IDH1/2 and TET2 by direct sequencing. Mutational analyses of NPM1, C/EBPa, Neuroblastoma rat sarcoma viral oncogene homolog (N-RAS), Kirsten RAS (K-RAS), DNMTa, IDH1/2 and TET2 were performed with PCR followed by direct sequencing. Specific sequences of primers used for PCR and sequencing are available upon request.
The entire coding sequence of C/EBPa and TET2 was sequenced to detect mutations because mutations in these genes are reportedly spread throughout the coding region. For NPM1 mutations, we directly sequenced exon 12 because most mutations reportedly occur in this region. For DNMT3a mutations, we directly sequenced the region of exon 23 that encodes the zinc-finger domain and methyltransferase domain, as mutations reportedly occur with high frequency in this region. Codons 12, 13 and 61 of N-RAS and codon 12 of K-RAS are known mutation hotspots. Thus, the hotspot-containing exon 2 and 3 regions of N-RAS and exon 2 of K-RAS were directly sequenced. Similarly, we sequenced the exon 4 region of IDH1 that contains a mutation hotspot at codon 132, and IDH2 that contains mutation hotspots at codons 140 and 172.
To validate the sequencing results, PCR products were inserted into the pCR2.1-TOPO vector using a TOPO TA cloning kit (Invitrogen, Carlsbad, CA, USA). Recombinant plasmids isolated from 8 to 12 white colonies were sequenced.
Statistical analysis
Patient characteristics were compared using w 2 -and Fisher tests. Statistical analyses were carried out using SPSS software (version 12.1.4; SPSS Inc., Chicago, IL, USA). Abbreviations: C/EBPa, CCAAT/enhancer-binding protein alpha; NPM1, Nucleophosmin 1; BSC, treatment with best supportive care alone; CR, complete remission. Table 1 shows the clinical background of patients. All 34 patients (20 men and 14 women; median age, 51.9 years; range, 17-77 years) were enrolled. All patients had de novo AML, with FrenchAmerican-British (FAB) classifications of M0 (1 case), M1 (13 cases), M2 (10 cases), M4 (5 cases), M5a (4 cases) and M5b (1 case). Chromosomal analysis at diagnosis was possible for all patients. The intermediate prognosis group comprised cases with normal chromosomes (17 patients), trisomy 8 (2 patients) and other types of chromosomal abnormalities (8 patients). The poor prognosis group comprised patients with 11q23 abnormality (4 cases), monosomy 7 (2 patients), inv(3) (1 patient), del(7q) (1 patient) and complex chromosomal abnormalities (1 patient), among which there was one patient with both monosomy 7 and inv(3), and one patient with both monosomy 7 and 11q23 abnormality. At diagnosis, at least one of the genetic mutations analyzed in this study was detected in 70.6% of all patients. Mutations were found at a high incidence of 81.5% of patients in the intermediate prognosis group, whereas mutations were found in only 28.6% of patients in the poor prognosis group. Moreover, chromosomal analysis revealed that although 16 patients (59.3%) in the intermediate prognosis group had two or more mutations, this was not the case in the poor prognosis group. In particular, mutations in FLT3-ITD known to be associated with poor prognosis were found in 11 patients (32.4%), and all patients with FLT3-ITD mutations belonged to the intermediate prognosis group. Of these patients, nine (81.8%) also had other mutations.
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RESULTS
Clinical background of patients
Standard intensive chemotherapy involved BHAC-DM-based therapy, [42] [43] [44] [45] DNR/Ara-C or IDA/Ara-C for the 32 patients at diagnosis. In two elderly patients, low-dose chemotherapy (that is, low-dose AraC therapy [46] [47] [48] ) was performed because AML was complicated with infection. Eleven patients (32.4%) were resistant to induction therapy, and achieved first remission after reinduction therapy. The median duration to first remission from initial presentation for all patients was 58.6 days (25-237 days), with a median duration of 58.7 days (25-237 days) for the intermediate prognosis group and 58.3 days (30-122 days) for the poor prognosis group. Sibling bone marrow transplant in the one patient in the poor prognosis group with 11q23-related AML was the only hematopoietic stem cell transplantation conducted at first remission. The median duration of first remission was 232.3 days (14-899 days), with a median duration of 142.1 days (24-261 days) for the poor prognosis group and 255.7 days (14-899 days) for the intermediate prognosis group. Although the period was shorter in the poor prognosis group, the difference was not significant (P ¼ 0.717). Among the patients in the intermediate prognosis group, the median duration of first remission was 175.0 days (28-684 days) for FLT3-ITD-positive patients and 311.6 days (14-899 days) for FLT3-ITD-negative patients. Although the duration of remission was shorter in FLT3-ITD-positive patients, the difference was not significant (P ¼ 0.751). Re-induction therapy Tables 3, 4 and 5, respectively. All results are summarized in Table 6 .
Of the mutations examined, cases for which new mutations were detected at relapse were FLT3-ITD mutations in two cases (Nos 14 and 26), FLT3-TKD mutation in 1 case (No. 34), N-RAS mutation in one case (No. 10) and K-RAS mutation in one case (No. 32). Mutations that were acquired at relapse were all class I mutations (Tables 3, 4 
and 5).
As shown in Tables 3-5 , the various detected mutations at diagnosis in almost all cases were also detected at relapse. On the basis of this, we speculate that clones positive for acquired mutations at relapse developed from founding clones at diagnosis.
Of the 11 patients that were positive for FLT3-ITD mutations at diagnosis, patient Nos 3, 6 and 8 lost the mutations at relapse (Table 3) . Specifically, Nos 3 and 6 had NPM1 mutations and No. 8 had a FLT3-TKD mutation at diagnosis, but those mutations in Nos 3 and 8 disappeared at relapse.
Moreover, for the three patients (Nos 8, 19 and 26) that were positive for FLT3-TKD mutations at diagnosis, the mutations were lost at relapse for all cases. It was therefore thought that FLT3-TKD mutation positive subclones existed at diagnosis disappeared at relapse.
As shown in Tables 4, 3 (Nos 3, 9 and 19) of the 12 cases that were NPM1 mutation-positive at diagnosis and 2 (Nos 10 and 12) of 5 cases that were C/EBPa mutation-positive at diagnosis lost the mutations at relapse. The lost C/EBPa mutations are all single mutations in N-terminal domain supposed that prognostic correlation is lower than double mutations. 1  Normal  ITD  ITD  ---NA  -NA  2  --------3  ITD  ----NA  -NA  4  ITD  ITD  ------5  ITD  ITD  ------6  I T D  -------7  ITD  ITD  ------8  ITD  -TKD  -----9 -
Abbreviations: ITD, internal tandem duplications; NA, not applicable; TKD, tyrosine kinase domain.
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As shown in Table 5 , there were no cases in which mutations in genes considered epigenetics-modifying genes, that is, DNMT3a, IDH1/2 and TET2 were acquired or lost at relapse. Through diagnosis and relapse, these mutations overlapped with various mutations.
DNMT3a mutations predict FLT3ITD mutation-positive AML at relapse Table 6 summarizes the various analyzed mutations. Consistent with previous reports, mutations in FLT3-ITD, FLT3-TKD, NPM1, DNMT3 and IDH1/2 or TET2 overlapped with mutations in other genes with high frequency. On the other hand, mutations in C/EBPa, MLL-PTD and N-RAS, K-RAS showed no clear trend of overlapping with other genes (Table 6) .
Upon examining whether mutation patterns at diagnosis can predict mutations at relapse, we observed that two cases with DNMT3a mutations at diagnosis acquired FLT3-ITD mutations at relapse. For seven cases of FLT3-ITD mutation-positive AML that did not harbor DNMT3a mutations, FLT3-ITD mutations were lost in three cases. Among the seven cases harboring DNMT3a mutations, FLT3-ITD mutations were detected at relapse in six cases (Table 6 ).
On the other hand, of 27 cases without DNMT3a mutations, FLT3-ITD mutations could be detected in only three cases at relapse. These findings suggest that for AML in which DNMT3a mutations exist at diagnosis, FLT3-ITD mutations were present at relapse at a high frequency (P ¼ 0.001). Moreover, the high frequency of FLT3-ITD mutations at relapse is also seen in AML cases that initially present with either IDH1/2 or TET2 mutations (Po0.001). The above results indicate the possibility that mutations in epigenetics-modifying genes may cause genetic instability and induce FLT3-ITD mutations, leading to resistance to therapy and relapse(Po0.001) ( Table 7) .
DISCUSSION
The present study is the first that aimed to analyze, from diagnosis to relapse, the various mutations that have been reported to be AML prognostic factors. Various facts became clear through this study.
In our analysis, compared with additional chromosomal abnormalities at relapse (62.5%), newly acquired molecular mutations at relapse were quite rare (14.7%). The fact that additional chromosomal abnormalities at relapse occurred at high 
Abbreviations: C/EBPa, CCAAT/enhancer-binding protein alpha; MLL-PTD, partial tandem duplication of myeloid/lymphoid or mixed-lineage leukemia; NPM1, Nucleophosmin 1.
a Several mutations types of NPM1 were described by Falini et al. 15 All NPM1 mutation were Mutation A type in this study.
b C/EBPa mutations within the first 300 base pairs of N-terminal lead to a frame-shift or premature stop codon eliminating p42 expression without affecting p30 translation. C-terminal insertions or deletions disrupt the bZIP domain and affect both p42 and p30 C/EBPa. C/EBPa mutations observed in AML frequently occur as biallelic mutations and cluster predominantly in the N-and C-terminal region of either allele. Furthermore, more recent studies comparing bi-allelic versus mono-allelic C/EBPa mutations as prognostic factor demonstrate that AMLs with bi-allelic C/EBPa mutations have favorable prognosis whereas AMLs with mono-allelic mutations in C/EBPa do not show difference in prognosis compared with wild-type C/EBPa AMLs.
Epigenetics-modifying gene mutations induce FLT3-ITD in relapsed AML S Wakita et al frequency in the poor prognosis group suggests that the mechanism of acquiring these additional chromosomal abnormalities likely differs from that of acquiring molecular mutations. Of the genes analyzed in this study, mutations were acquired at relapse only in FLT3-ITD, FLT3-TKD, N-RAS and K-RAS. Previous studies have reported that FLT3-ITD mutations are detected only at relapse, in 4-8% of cases. 49, 50 Moreover, the fact that various different ITD mutation subtypes can be detected simultaneously at diagnosis suggests that mutations in FLT3-ITD-positive clones arise from one of many subclones. 51 We also previously reported that cells that comprised a small subclone group at diagnosis become dominant at relapse in t(8;21) AML cases with c-kit mutations. 34 The fact that additional mutations were all class I mutations supports the hypothesis that a stage before leukemia or a stage of low-grade leukemia exists in which gain of function mutations in genes related to cell proliferation are acquired, leading to leukemia and resistance to therapy.
We also found that many mutations were lost during the clinical course of AML. In most of cases, FLT3-TKD mutations were lost at relapse. The association between FLT3-TKD mutations and prognosis has been controversial. 52 Our results also indicate the low likelihood that they have an important role in resistance to therapy. With respect to FLT3-ITD as well, 30% of patients lost mutations at relapse. This is consistent with previous studies reporting the loss of FLT3-ITD mutations. 50, 51, 53 Recent studies have also shown with knockin mice that the FLT3-ITD mutant allele is suppressed when the wild-type allele is expressed, and that FLT3-ITD-positive cells do not exhibit explosive proliferation. 54, 55 Even in the clinical setting, loss of heterozygosity of FLT3-ITD is a potential prognostic factor, 56 and the ratio of the wild-type allele to FLT3-ITD mutant allele may predict the prognosis of FLT3-ITDpositive patients after transplantation. 57 When FLT3-ITD-positive subclones remain a small group, a good prognosis might be achieved by tailoring therapy accordingly. Surprisingly, we found that class II mutations that are conventionally thought to be first hit mutations (for example, mutations in NPM1 and C/EBPa) are lost at a certain frequency. A large cohort study demonstrated that cases of mutations in AML often involve both class I and II mutations, and that cases with only class I or class II mutations were rare, 22 suggesting that the 'two hit model' is generally accurate. However, this model cannot explain the loss of class II mutation-positive clones at the onset of leukemia. On the other hand, mutations in epigenetics-modifying genes, such as DNMT3a, IDH1/2 and TET2, did not differ at diagnosis and relapse, suggesting the possibility that the onset of leukemia may result from mutations in genes that lead to genetic instability.
Ding et al. 33 recently reported the whole-genome analysis of initial and relapsed AML using next generation sequencers. Two possibilities regarding AML relapse were proposed: (1) founding clones gain mutations and evolve into relapse clones, and (2) subclones with different mutations exist among founding clones, and a subclone from this population expands at relapse. They also reported that in addition to the major mutations, mutations in WAC, SMC3, DIS3, DDX41, DAXX are also observed at relapse. Discovering new mutations acquired at relapse with high frequency may help uncover the mechanisms underlying AML relapse. 
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Our results have important implications in MRD analysis that use clinically relevant mutations. In addition to NPM1, which is being considered as a practical MRD marker, 35 we confirmed that a number of mutations are lost at relapse. However, although few, some mutations remained from diagnosis through relapse, such as those in DNMT3a, IDH1/2 and TET2. Thus, the utility of mutations in epigenetics-modifying genes as MRD markers should be examined.
Genetic analysis of paired initial and relapse samples allows one to follow the course of how a founding clone becomes a relapse clone, thereby potentially revealing the mechanisms underlying AML relapse. Here, we discovered that the presence of mutations in epigenetics-modifying genes at diagnosis was associated with the presence of FLT3-ITD-positive clones at relapse. This suggests the possibility that an initial mutation in an epigenetics-modifying gene leads to genetic instability, thereby promoting FLT3-ITD mutations and the expansion of FLT3-ITD-positive clones. This, in turn, may be related to resistance to therapy and relapse. Indeed, DNMT3a mutations can be used to classify the prognosis of FLT3-ITDpositive cases, 23 strongly suggesting that DNMT3a mutations have a role in the responsiveness of FLT3-ITD-positive cases to chemotherapy. Although many tyrosine kinase inhibitors that target FLT3-ITD are being developed and many clinical studies have been carried out in Europe and the United States, their efficacy has only been shown in a subset of cases. 36, 37 DNMT3a mutations and other mutations in epigenetics-modifying genes are anticipated to allow for stratification of the responsiveness to these molecular target drugs. Table 6 . Summary of the mutation status of 34 AML patients at diagnosis and relapse Columns D and R show the result of the mutation analyses at diagnosis and relapse, respectively. Nonspecific means nonspecific karyotype abnormality. Colored grids mean mutation positive and light-colored grids mean that the mutation turned to negative. Black grids mean that samples were not assessed for analysis. Abbreviations: CI, confidence interval; DNMT3a, DNA-methyltransferase 3 alpha; FLT3-ITD, internal tandem duplications of Fms-like tyrosine kinase 3; IDH, isocitrate dehydrogenase; TET, tet methylcytosine dioxygenase.
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